Deciphera Pharmaceuticals DCPH 深 沪
等待开盘 11-05 09:30:00 美东时间
25.59
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 25.59
- 总市值 206.77万
- 52周最高 25.61
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 9.90
- 委 比 0.00%
- 总股本 8.08万
- 历史最高 71.11
- 量 比 0
- 振 幅 0.00%
- 历史最低 6.51
- 每 手 1
- 风险率 4.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer
MBX Biosciences appoints Jeff Held as Chief Legal Officer. With over 30 years of experience in biotech and healthcare, Held will support the company's growth and strategic initiatives. MBX granted him an inducement equity award, including stock options and RSUs, as part of his appointment. The company focuses on developing precision peptide therapies for endocrine and metabolic disorders.
09-08 12:00
Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update
Replimune Group announced the FDA accelerated approval of TUDRIQEV™ in combination with nivolumab for advanced melanoma, with U.S. launch expected within 60 days. The company secured $150 million in financing to support commercialization and the IGNYTE-3 confirmatory trial. Michelle DiNapoli was appointed Chief Commercial Officer, bringing extensive oncology experience. Replimune reported a cash balance of $195.3 million as of June 30, 2026, and ...
08-14 12:00
MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth
MBX Biosciences announces leadership changes: Steve Hoerter appointed as CEO, replacing Kent Hawryluk, and John Smither as CFO. Hoerter, a biotech veteran, succeeds Hawryluk, who co-founded the company and led its growth. The company remains focused on advancing precision peptide therapies for endocrine and metabolic disorders, with key milestones expected in 2026.
07-13 20:15
J.P. Morgan Life Sciences Private Capital Welcomes Dashyant Dhanak, Ph.D. as Venture Partner
NEW YORK, May 19, 2025 /PRNewswire/ -- J.P. Morgan Life Sciences Private Capital, the life sciences venture and growth equity arm within J.P. Morgan Asset Management, today announced the app...
2025-05-19 22:00
Ono Pharmaceutical completes tender offer for Deciphera
Ono Pharmaceutical has successfully completed its $2.4B tender offer for Deciphera Pharmaceuticals (NASDAQ:DCPH). As a result of the transaction, Deciphera is now a wholly owned subsidiary of Ono, wit...
2024-06-11 22:22
Deciphera Pharmaceuticals: Significant Post-Merger Corporate Changes
An update from Deciphera Pharmaceuticals (DCPH) is now available. Following the...
2024-06-11 21:59
